MRN gets SMART with its clinical trial scheduling
pharmafile | June 28, 2012 | News story | Research and Development | clinical trials, electronic data capture, medical research network, mrn, patient scheduling
Medical Research Network (MRN), the unique Clinical Trial Support Organisation (CTSO) offering home trial and site nurse support as well as bespoke recruitment and retention services, has unveiled the deployment of its new patient scheduling tool to manage, report and track clinical trial projects in real time.
MRN-SMART, announced at the DIA Annual Meeting in Philadelphia, incorporates a digital pen data capture facility, ensuring all source data compiled in the patient’s home is rapidly transmitted to the clinical trial site.
When MRN’s nurses visit patients in the home they can complete their records forms as usual however now data is now also automatically stored electronically on a central network which provides automatic tracking, enhanced visibility of trial data and increased security.
Dr Graham Wylie, CEO of MRN, commented: “We always strive for efficiency and effectiveness in all that we do. We work to defined quality management systems and are continually developing our tools to truly globalise the delivery of homecare in clinical trials.
“With MRN-SMART we offer greater security, real-time access to trial information and create cost savings.”
MRN-SMART is part of the MRN INNOVATION suite of tools and integrates with MRN-TEC, an interactive online portal offering study-specific and GCP training for nurses within MRN projects. The suite gives MRN a unique capability to train and manage large teams across the globe. Completing the MRN-INNOVATION suite is MRN-COMPLY, a quality and compliance system ensuring high standards of care across all global trials.
Dr Wylie added: “I’m delighted to be launching MRN-SMART; it’s going to significantly help to combat the challenges posed by operating clinical trials across multiple timelines, numerous continents and time zones.”
For further information on MRN-SMART and the MRN-INNOVATION suite of tools visit www.themrn.co.uk.
Related Content
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
FDA clears Aruna Bio’s IND for AB126 to enter clinical trials
Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based …
